MarketCapExport financials
Dr. Reddy's Laboratories Limited (RDY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Dr. Reddy's Laboratories Limited Income Statement 2025-2011 | RDY
Brief overview of income trends at Dr. Reddy's Laboratories Limited
The conclusions below are based on five years of reported results. Revenue at Dr. Reddy's Laboratories Limited moved from 175 billion INR in 2020 to 326 billion INR in 2025. The total change was +86.4%, with a CAGR of approximately 13.3%. Top-line growth remained consistently strong over the period.
Gross profit changed from 94 billion INR to 190 billion INR (+102.6%). The cost base moved more slowly than the top line, which supported margins. The gross margin was 53.8% at the start and 58.5% at the end. The business retained more gross profit from each unit of revenue.
The operating result measured by EBITDA moved from 45.2 billion INR to 71.8 billion INR, or +58.8%. EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from 25.9% to 22.1%. Operating return per unit of revenue declined.
The net result moved from 19.5 billion INR to 57.2 billion INR, or +193.6%. Net profit ended the five years at a local peak.
Conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. The financial profile benefits from a stronger final result, a larger revenue base and better sales economics. Caution is warranted because of a declining EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Dr. Reddy's Laboratories Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
12.3 B | 11.6 B | 9.27 B | 1.83 B | 10.8 B | 8.49 B | -2.18 B | -1.68 B | -2.12 B | -4.01 B | -4.57 B | 8.88 B | 11.4 B | 10.2 B | 8.28 B |
Shares |
833 M | 832 M | 830 M | 166 M | 166 M | 166 M | -52 M | -52 M | -52 M | -88 M | -88 M | 197 M | 302 M | 302 M | 211 M |
Historical Prices |
14.7 | 13.9 | 11.2 | 11.1 | 65.4 | 71 | 40.1 | 37 | 36.5 | 43.7 | 44.5 | 48.2 | 38.9 | 31.4 | 27.5 |
Net Income |
57.2 B | 55.7 B | 45.1 B | 23.6 B | 17.2 B | 19.5 B | - | - | - | - | - | - | - | - | 310 M |
Revenue |
326 B | 279 B | 246 B | 214 B | 190 B | 175 B | 2.22 B | 2.18 B | 2.17 B | 2.34 B | 2.38 B | 2.2 B | - | - | 1.68 B |
Cost of Revenue |
135 B | 116 B | 107 B | 101 B | 86.6 B | 80.6 B | 70.4 B | 65.7 B | 62.5 B | 62.4 B | - | - | - | - | - |
Gross Profit |
190 B | 164 B | 139 B | 114 B | 103 B | 94 B | 1.21 B | 1.17 B | 1.21 B | 1.39 B | 1.37 B | 1.26 B | - | - | 904 M |
Operating Income |
71.8 B | 67.7 B | 57.1 B | 29.5 B | 24.3 B | 16 B | 20.9 B | 11.9 B | 13.5 B | 29.6 B | - | - | - | - | - |
Interest Expense |
2.83 B | 1.71 B | 1.43 B | 958 M | 970 M | 983 M | 889 M | 788 M | 634 M | 826 M | - | - | - | - | - |
EBITDA |
71.8 B | 67.7 B | 57.1 B | 29.5 B | 24.3 B | 45.2 B | 176 M | 180 M | 174 M | 155 M | 130 M | 118 M | 102 M | 102 M | 372 M |
Operating Expenses |
119 B | 95.9 B | 82.2 B | 84.4 B | 78.8 B | 61.2 B | 63.8 B | 64.3 B | 64.8 B | 62.6 B | 59 B | 49.8 B | 38.9 B | 34 B | 27.6 B |
General and Administrative Expenses |
93.9 B | 77.2 B | 68 B | 62.1 B | 54.6 B | 50.1 B | 707 M | 720 M | 715 M | 690 M | 683 M | 646 M | - | - | 532 M |
All numbers in INR currency
Quarterly Income Statement Dr. Reddy's Laboratories Limited
| 2025-Q4 | 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 833 M | - | 832 M | - | 830 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | 57.2 B | - | 55.7 B | - | 45.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | 326 B | - | 279 B | - | 246 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | 135 B | - | 116 B | - | 107 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 190 B | - | 164 B | - | 139 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | 71.8 B | - | 67.7 B | - | 57.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | 2.83 B | - | 1.71 B | - | 1.43 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | 71.8 B | - | 67.7 B | - | 57.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | 119 B | - | 95.9 B | - | 82.2 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | 93.9 B | - | 77.2 B | - | 68 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in INR currency
The income statement is one of the three key financial reports of a company Dr. Reddy's Laboratories Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Israel
Canada
Schweiz
China
Britain
Irlanda
